Role of Dopamine Receptors in Primary Focal Dystonias
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01373840
Recruitment Status :
First Posted : June 15, 2011
Last Update Posted : May 15, 2018
Washington University School of Medicine
National Institute of Neurological Disorders and Stroke (NINDS)
Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in the U.S. While the pathophysiology of dystonia remains uncertain the treatment is rather rudimentary. A better understanding of neural mechanisms of dystonias is not only an invaluable prerequisite for developing better treatment options but also a step toward better understanding of the complex network of basal ganglia. In this study I will investigate if there is any difference between the dopamine receptors and dopamine in people with dystonia and healthy subjects.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
21 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Any healthy control or patient with primary focal dystonia or arm or face.
Male or Female
Any race or ethnicity
Primary focal dystonia (arm or cranial)
Ability to give informed consent
Family history of dystonia
Pregnancy (confirmed with negative urine pregnancy test in women of child bearing potential), breastfeeding
Exposure to radiation therapy
Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm clip etc.
History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening phase
History of exposure to any drugs affecting dopaminergic systems within the last 6 months (e.g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine, reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor binding or endogenous dopamine).
Active depression (Beck Depression Inventory_II >14)
Cognitive impairment (Mini-Mental State Score <27)
CNS active medications such as gabapentin or narcotics, muscle relaxants which might be given for pain in the 3 days prior to study
History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism, inability to hold head still during the scanning time.